SPDR S&P Biotech ETF
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
23.13% more ownership
Funds ownership: 156.61% [Q4 2024] → 179.74% (+23.13%) [Q1 2025]
7% less capital invested
Capital invested by funds: $9.84B [Q4 2024] → $9.19B (-$647M) [Q1 2025]
7% less funds holding in top 10
Funds holding in top 10: 15 [Q4 2024] → 14 (-1) [Q1 2025]
8% less funds holding
Funds holding: 727 [Q4 2024] → 667 (-60) [Q1 2025]
34% less repeat investments, than reductions
Existing positions increased: 175 | Existing positions reduced: 265
39% less first-time investments, than exits
New positions opened: 73 | Existing positions closed: 119
50% less call options, than puts
Call options by funds: $1.08B | Put options by funds: $2.17B
Research analyst outlook
We haven’t received any recent analyst ratings for XBI.
Financial journalist opinion
Neutral
Zacks Investment Research
3 days ago
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund launched on 01/31/2006.
Neutral
Seeking Alpha
2 weeks ago
Healthcare Sector Checkup As U.S. Looks To Change Regulations
Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.
Negative
Market Watch
1 month ago
Trump is right about drug prices. He's just going about it all wrong.
The stock market doesn't believe the president about prescription drugs.
Neutral
Seeking Alpha
1 month ago
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Positive
Zacks Investment Research
1 month ago
Surprise Breakthrough: US-China Talks Spark Market Rally
An unexpected thaw in US-China trade relations is sending US equity markets soaring this morning.
Neutral
CNBC Television
1 month ago
StemPoint's Michelle Ross breaks down navigating the pharmaceutical sector volatility
Michelle Ross, StemPoint Capital CIO, joins 'Closing Bell' to discuss health care's weak week and how to navigate pharma volatility.
Neutral
CNBC Television
1 month ago
New vaccine chief rocks pharmaceutical stocks
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
Neutral
Zacks Investment Research
1 month ago
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
The SPDR S&P Biotech ETF (XBI) was launched on 01/31/2006, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
Neutral
CNBC Television
1 month ago
We're in a pharma stock pickers market, says Kessef's Len Yaffe
Len Yaffe, Kessef Capital Management, joins 'Fast Money' to talk opportunities in the pharma stock space.
Negative
CNBC Television
2 months ago
Sell into strength in pharma, says Mizuho's Jared Holz
Jared Holz, Mizuho, joins 'Fast Money' to talk a rebound in biotech stocks and what new tariffs mean for the pharmaceuticals space.
Charts implemented using Lightweight Charts™